Risk for retinal vascular occlusion not increased with female hormone therapy use
Click Here to Manage Email Alerts
Women who filled a prescription for female hormone therapy did not have an increased risk for retinal vein occlusion or retinal artery occlusion, according to findings published in JAMA Ophthalmology.
“Given that retinal vascular occlusions share similar risk factors to those of cardiovascular and cerebrovascular diseases, it is therefore reasonable to suspect the FHT may predispose toward retinal vascular occlusion,” Delu Song, MD, and colleagues wrote.
However, no significant association was found between filling a prescription for female hormone therapy (FHT) and all outcomes after subanalyses that were stratified by age, diabetes and hypertension.
The multiple-cohort study matched 205,304 women (mean age, 47.2 years; white, 71%) who filled a prescription for FHT with 755,462 controls. The primary outcome measure was a new diagnosis of retinal vein occlusion or retinal artery occlusion.
Among the female hormone therapy cohort, 41 cases (0.01%) of retinal artery occlusion and 68 cases (0.02%) of retinal vein occlusion occurred, compared with 373 cases (0.05%) of retinal artery occlusion and 617 cases (0.08%) of retinal vein occlusion among controls. There was no significant difference in risk for retinal artery occlusion, retinal vein occlusion or combined outcomes after inverse probability of treatment weighting.
“These findings suggest that filling a prescription for FHT, and presumably taking FHT, does not increase the risk” for retinal artery or vein occlusion, the authors wrote.
Collapse
Read more about
Click Here to Manage Email Alerts